General Practice Comprehensive Consultation Note

Patient Demographics

• Patient Name: Arthur Pendelton
• Date of Birth: 14/05/1962
• Gender: Male
• Contact Information: 42 Banksia Street, Heidelberg VIC 3084; Mobile: 0412 398 765
• Emergency Contact Information: Margaret Pendelton (Wife) - 0412 398 766
• Primary Care Provider: Dr Sarah Jenkins
• Insurance Information: Medicare: 2948 57102 1; Bupa Health Insurance (Member ID: 88392014)

Vital Signs

• Blood Pressure: 148/92 mmHg
• Heart Rate: 78 bpm
• Respiratory Rate: 16 breaths/min
• Temperature: 36.8 °C
• Oxygen Saturation: 98 % on RA
• Weight: 94.5 kg
• Height: 178 cm
• BMI: 29.8 kg/m²
• Pain Level: 4/10 (right 1st MTP joint, resolving)

Medical History

• Chronic Conditions: Type 2 Diabetes Mellitus (diagnosed 10/2018, diet and pharmacologically controlled); Essential Hypertension (diagnosed 03/2015); Gout (recurrent, acute flare right hallux 3 weeks ago, diagnosed 2021)
• Previous Surgeries: Laparoscopic cholecystectomy (12/11/2014, uncomplicated recovery); Right inguinal hernia repair (04/08/2019, mesh repair, no recurrence)
• Family History of Diseases: Father: Myocardial infarction at age 64, T2DM; Mother: Osteoarthritis, Hypertension
• Social History: Ex-smoker (ceased 2010, 15 pack-year history); Alcohol: 2–3 standard drinks (beer) 4 nights/week; Retired accountant, lives with wife, independent ADLs
• Psychiatric History: Mild adjustment disorder with anxious mood (2020, resolved with short-term CBT)

Immunization Records

• Vaccines Administered: Influenza vaccine (Fluzone High-Dose Quadrivalent) administered 15/04/2024; Shingrix (Dose 1) administered 10/01/2024
• Vaccines Due: Shingrix (Dose 2) due 10/07/2024; COVID-19 booster due 10/2024

Medications

• Current Medications: metformin (Diabex®) 1,000 mg PO BID (ongoing); perindopril (Coversyl®) 5 mg PO daily (ongoing); atorvastatin (Lipitor®) 20 mg PO nocte (ongoing)
• Past Medications: colchicine (Lengout®) 500 mcg PO BID (stopped 10 days ago following resolution of acute gout flare); ramipril (Tritace®) 5 mg PO daily (ceased 06/2015 due to intractable dry cough)
• Herbal Supplements: Krill oil 1,000 mg PO daily; Magnesium chelate 500 mg PO daily

Allergies

• Drug Allergies: Penicillin (generalised maculopapular rash); Ramipril (ACE-I induced cough, though tolerates perindopril)
• Food Allergies: Shellfish (mild urticaria)
• Environmental Allergies: Grass pollen (seasonal allergic rhinitis)

Diagnosis

• Primary Diagnosis: Suboptimally controlled Type 2 Diabetes Mellitus with rising HbA1c
• Secondary Diagnoses: Essential Hypertension (above target < 130/80 mmHg); Chronic tophaceous gout (intercritical phase, hyperuricaemia)
• ICD-10 Codes: E11.9, I10, M10.9

Laboratory Results

• Blood Work Results: HbA1c: 7.8 % (62 mmol/mol); Fasting Glucose: 8.4 mmol/L; eGFR: 74 mL/min/1.73m²; Serum Urate: 0.52 mmol/L (elevated); Total Cholesterol: 4.2 mmol/L, LDL: 2.1 mmol/L, HDL: 1.1 mmol/L, Triglycerides: 2.2 mmol/L; FBE and LFTs: NAD (collected 18/05/2024)
• Imaging Results: Right foot X-ray (02/05/2024): Mild periarticular erosions at 1st MTP joint consistent with gouty arthropathy, no fracture or osteomyelitis
• Other Diagnostic Results: Urine ACR: 1.8 mg/mmol (normal); 12-lead ECG (today at 10:15): Normal sinus rhythm, rate 76 bpm, no ischaemic changes

Treatment Plan

• Medications Prescribed: empagliflozin (Jardiance®) 10 mg PO daily (new, ongoing); perindopril/amlodipine (Coveram®) 5 mg/5 mg PO daily (replaces perindopril monotherapy, ongoing); allopurinol (Progout®) 100 mg PO daily (new urate-lowering therapy, ongoing); colchicine (Lengout®) 500 mcg PO daily (prophylaxis during allopurinol initiation, for 3 months)
• Referrals: GP Management Plan (GPMP) and Team Care Arrangements (TCA) updated: referred to Podiatry (Footscape Clinic) for annual diabetic foot check and Dietitian for glycaemic/low-purine dietary review
• Further Investigations: Repeat UEC, LFTs, Serum Urate, and HbA1c in 3 months (due 08/2024)
• Lifestyle Modifications: Reduce alcohol intake (particularly beer) to < 10 standard drinks/week with at least 2 alcohol-free days; initiate brisk walking 30 mins 5 days/week; low-purine, low-GI diet
• Follow-up Appointments: Review in 4 weeks (21/06/2024 at 09:30) to check BP response to Coveram, assess medication tolerance, and titrate allopurinol

Patient Education

• Information Provided: Diabetes Australia fact sheet on SGLT2 inhibitors; Arthritis Australia "Gout and Diet" patient handout
• Counseling Given: Discussed mechanism and side effects of empagliflozin, specifically mycotic genital infections, UTI risk, and euglycaemic DKA ("sick day" management: withhold if acutely unwell, vomiting, or fasting for surgery). Explained rationale for starting allopurinol at low dose with colchicine cover to prevent flare-ups, and not to cease allopurinol if an acute flare occurs.
• Follow-up Instructions: Monitor home BP twice daily for 1 week prior to next visit. Present to clinic or urgent care immediately if experiencing severe dizziness, signs of DKA (nausea, abdominal pain, tachypnoea), or widespread skin rash after starting allopurinol.